Literature DB >> 27605670

Cross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Trafficking.

Roy S Song1, Rosa Tolentino1, Eric A Sobie1, Susana R Neves-Zaph2.   

Abstract

Dopamine, a key striatal neuromodulator, increases synaptic strength by promoting surface insertion and/or retention of AMPA receptors (AMPARs). This process is mediated by the phosphorylation of the GluA1 subunit of AMPAR by cyclic nucleotide-dependent kinases, making cyclic nucleotide phosphodiesterases (PDEs) potential regulators of synaptic strength. In this study, we examined the role of phosphodiesterase 2 (PDE2), a medium spiny neuron-enriched and cGMP-activated PDE, in AMPAR trafficking. We found that inhibiting PDE2 resulted in enhancement of dopamine-induced surface GluA1 expression in dopamine receptor 1-expressing medium spiny neurons. Using pharmacological and genetic approaches, we found that inhibition of PDE1 resulted in a decrease in surface AMPAR levels because of the allosteric activation of PDE2. The cross-regulation of PDE1 and PDE2 activities results in counterintuitive control of surface AMPAR expression, making it possible to regulate the directionality and magnitude of AMPAR trafficking.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  AMPA receptor (AMPAR); GluA1; PDE1; PDE2; cAMP; cGMP; dopamine; phosphodiesterases; trafficking

Mesh:

Substances:

Year:  2016        PMID: 27605670      PMCID: PMC5087742          DOI: 10.1074/jbc.M116.749747

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

1.  Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo.

Authors:  G L Snyder; P B Allen; A A Fienberg; C G Valle; R L Huganir; A C Nairn; P Greengard
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

2.  The use of pHluorins for optical measurements of presynaptic activity.

Authors:  S Sankaranarayanan; D De Angelis; J E Rothman; T A Ryan
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

3.  Activation of PDE10 and PDE11 phosphodiesterases.

Authors:  Ronald Jäger; Corina Russwurm; Frank Schwede; Hans-Gottfried Genieser; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

4.  Activation of D1 dopamine receptors increases surface expression of AMPA receptors and facilitates their synaptic incorporation in cultured hippocampal neurons.

Authors:  Can Gao; Xiu Sun; Marina E Wolf
Journal:  J Neurochem       Date:  2006-06-27       Impact factor: 5.372

5.  The distribution of phosphodiesterase 2A in the rat brain.

Authors:  D T Stephenson; T M Coskran; M P Kelly; R J Kleiman; D Morton; S M O'Neill; C J Schmidt; R J Weinberg; F S Menniti
Journal:  Neuroscience       Date:  2012-09-19       Impact factor: 3.590

6.  Selective expression of one Ca(2+)-inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions.

Authors:  N Mons; D M Cooper
Journal:  Brain Res Mol Brain Res       Date:  1994-03

7.  The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding.

Authors:  Sergio E Martinez; Albert Y Wu; Natalie A Glavas; Xiao-Bo Tang; Stewart Turley; Wim G J Hol; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

8.  Engineering of a red-light-activated human cAMP/cGMP-specific phosphodiesterase.

Authors:  Carlos Gasser; Sandra Taiber; Chen-Min Yeh; Charlotte Helene Wittig; Peter Hegemann; Soojin Ryu; Frank Wunder; Andreas Möglich
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

9.  Nitric Oxide-Soluble Guanylyl Cyclase-Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease?

Authors:  Anthony R West; Kuei Y Tseng
Journal:  Front Syst Neurosci       Date:  2011-06-30

10.  Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32

Authors:  Marina Polito; Elvire Guiot; Giuseppe Gangarossa; Sophie Longueville; Mohamed Doulazmi; Emmanuel Valjent; Denis Hervé; Jean-Antoine Girault; Danièle Paupardin-Tritsch; Liliana R V Castro; Pierre Vincent
Journal:  eNeuro       Date:  2015-08-31
View more
  3 in total

1.  Puncta of Neuronal Nitric Oxide Synthase (nNOS) Mediate NMDA Receptor Signaling in the Auditory Midbrain.

Authors:  Bas M J Olthof; Sarah E Gartside; Adrian Rees
Journal:  J Neurosci       Date:  2018-12-07       Impact factor: 6.167

Review 2.  A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration.

Authors:  Giovanni Ribaudo; Maurizio Memo; Alessandra Gianoncelli
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

3.  Pharmacological Inhibition of Epac1 Averts Ferroptosis Cell Death by Preserving Mitochondrial Integrity.

Authors:  Nshunge Musheshe; Asmaa Oun; Angélica María Sabogal-Guáqueta; Marina Trombetta-Lima; Sarah C Mitchel; Ahmed Adzemovic; Oliver Speek; Francesca Morra; Christina H J T van der Veen; Frank Lezoualc'h; Xiaodong Cheng; Martina Schmidt; Amalia M Dolga
Journal:  Antioxidants (Basel)       Date:  2022-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.